Related Experiment Video
Updated: Aug 20, 2025
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Designing a humanized immunotoxin based on DELTA-stichotoxin-Hmg2a toxin: an in silico study
Zeinab Ghesmati1, Samira Mokhtari2, Maliheh Parvanak3
1Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Breast cancer remains the most frequently diagnosed cancer and the principal cause of mortality by malignancy in women. HER2 positive subtype includes 15-20% of breast cancer cases. This receptor could be an appropriate mark for targeting breast cancer cells. Immunotherapy methods compared to current cancer treatment methods have the lowest side effects. DELTA-stichotoxin-Hmg2a is isolated from the sea anemone and kills cells through pore formation. In the current study, we designed and evaluated an immunotoxin composed of pertuzumab and DELTA-stichotoxin-Hmg2a-derived scFv by bioinformatics tools. The designed immunotoxin was constructed using the amino acid sequences. Then, secondary structure and physico-chemical features were studied, and the tertiary structure of the immunotoxin was built according to the homology modeling methods. The validation and allergenicity of the model were assessed. The immunotoxin and receptor were docked and molecular dynamics simulation indicated the construct stability. The analysis results indicated that the construct is a stable protein that could have a natural-like structure and would not be an allergen, so this immunotoxin could effectively target HER2 receptors. Therefore, our designed immunotoxin could be an appropriate immunotoxin against HER2-positive breast cancer and could be a challenging topic for future in vitro and in vivo studies.
Insights
Researchers designed a novel immunotoxin targeting HER2-positive breast cancer. This construct, combining pertuzumab and DELTA-stichotoxin-Hmg2a, shows potential as a stable, non-allergenic therapeutic for HER2-positive breast cancer.
Area of Science:
- Oncology
- Biotechnology
- Immunology
Background:
- Breast cancer is a leading cause of cancer mortality in women, with HER2-positive subtypes accounting for 15-20% of cases.
- Targeting the HER2 receptor offers a promising strategy for HER2-positive breast cancer treatment.
- Immunotherapy presents a low-side-effect alternative to conventional cancer therapies.
Purpose of the Study:
- To design and computationally evaluate a novel immunotoxin targeting HER2-positive breast cancer.
- To assess the structural stability, natural-like structure, and non-allergenic potential of the designed immunotoxin.
- To investigate the binding affinity and stability of the immunotoxin with the HER2 receptor.
Main Methods:
- Bioinformatic tools were employed to design an immunotoxin.
- Amino acid sequences were used for construct design, followed by secondary and tertiary structure modeling.
- Homology modeling, model validation, allergenicity assessment, molecular docking, and molecular dynamics simulations were performed.
Main Results:
- The designed immunotoxin demonstrated a stable protein structure with natural-like characteristics.
- Computational analysis indicated the immunotoxin is non-allergenic.
- Docking and simulation studies confirmed effective targeting and stability with HER2 receptors.
Conclusions:
- The designed immunotoxin is a stable, non-allergenic protein with the potential to effectively target HER2 receptors.
- This novel immunotoxin represents a promising candidate for future in vitro and in vivo studies against HER2-positive breast cancer.
- The findings support further development of this immunotoxin as a targeted immunotherapy for breast cancer.
